GLP-1 RAs held therapeutic potential for KOA patients with obesity or diabetes, but current evidence remained insufficient, warranting further high-quality RCTs and mechanistic studies to confirm their efficacy and safety. Here, GCG is linked to obesity due to melanocortin 4 receptor deficiency.